Stroke prevention in atrial fibrillation: An Asian perspective

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. In 2050, it is estimated that there will be 72 million AF patients in Asia, accounting for almost 2.9 million patients suffering from AF-associated stroke. Asian AF patients share similar risk factor profiles as non-Asians, except that more Asians have a history of previous stroke. Clinical challenges are evident in the field of stroke prevention in AF, amongst Asians. Existing stroke and bleeding risk scores have not been well-validated in Asians. Asians are prone to bleeding when treated with warfarin, and the optimal international normalised ratio (INR) for warfarin use is yet to be determined in Asians, though Asian physicians tend to keep it in a lower range (e.g. INR 1.6-2.6) for elderly patients despite limited evidence to justify this. In general, warfarin is 'difficult' to use in Asians due to higher risk of bleeding and higher stroke rate in Asians than in non-Asians, as shown in randomised controlled trials. Excess of bleeding was not found in Asians when novel oral anticoagulants (NOACs) were used. Besides, the superiority of NOACs to warfarin in reducing thromboembolism was maintained in Asians. Therefore NOACs are preferentially indicated in Asians in terms of both efficacy and safety. Also, some preliminary data suggest that Asian patients with AF might not be the same. Future prospective randomised trials are needed for the selection of NOACs according to different ethnic background.

[1]  C. Chiang,et al.  Atrial fibrillation management in Asia: from the Asian expert forum on atrial fibrillation. , 2013, International journal of cardiology.

[2]  M. Zubaid,et al.  Stroke prevention in atrial fibrillation--an Asian stroke perspective. , 2013, Heart rhythm.

[3]  G. Lip,et al.  General mechanisms of coagulation and targets of anticoagulants (Section I) , 2013, Thrombosis and Haemostasis.

[4]  K. Minematsu,et al.  Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. , 2001, Internal medicine.

[5]  Y. Chun,et al.  Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. , 2013, Journal of cardiology.

[6]  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.

[7]  Lian-Yu Lin,et al.  Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. , 2011, Atherosclerosis.

[8]  I. Kubota,et al.  Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[9]  Emma Heeley,et al.  Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. , 2008, American heart journal.

[10]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[11]  Ale Algra,et al.  Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis , 2010, The Lancet Neurology.

[12]  J. Plumb,et al.  Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[13]  G. Breithardt,et al.  The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. , 2010, The American journal of cardiology.

[14]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[15]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[16]  Jun Zhu,et al.  Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in East Asia , 2013 .

[17]  H. Echizen,et al.  Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients , 2003, Clinical pharmacology and therapeutics.

[18]  C. Chiang,et al.  Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: insights from the RealiseAF Taiwanese cohort. , 2014, Journal of cardiology.

[19]  D. Lane,et al.  Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial , 2013, Thrombosis and Haemostasis.

[20]  J. Olesen,et al.  The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study , 2012, Thrombosis and Haemostasis.

[21]  M. Orii,et al.  Relationship between CHADS2 score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation. , 2010, International heart journal.

[22]  G. Lip,et al.  Vitamin K antagonists in heart disease: Current status and perspectives (Section III) , 2013, Thrombosis and Haemostasis.

[23]  H. Sawada,et al.  Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[24]  Yutao Guo,et al.  Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. , 2013, International journal of cardiology.

[25]  G. Lip,et al.  Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation , 2012, Thrombosis and Haemostasis.

[26]  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[27]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[28]  A. Waldo,et al.  Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme , 2009 .

[29]  G. Lip,et al.  Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT 2 R 2 Score , 2022 .

[30]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[31]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[32]  J. You,et al.  Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? , 2005, British journal of clinical pharmacology.

[33]  R. de Caterina,et al.  Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) , 2013, Thrombosis and Haemostasis.

[34]  T. Yamaguchi.  Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. , 2000, Stroke.

[35]  Wansu Chen,et al.  Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[36]  G. Lip,et al.  The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. , 2013, Journal of the American College of Cardiology.

[37]  G. Lip,et al.  Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact? , 2013, International journal of cardiology.

[38]  K. Okumura,et al.  Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) : Digest Version , 2010 .

[39]  M. Ozdemir,et al.  Dabigatran Versus Warfarin in Atrial Fibrillation , 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[40]  B. Dimitrov,et al.  Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke , 2011, Thrombosis and Haemostasis.

[41]  G. Lip,et al.  The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. , 2013, European heart journal.

[42]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[43]  G. Lip,et al.  Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. , 2013, International journal of cardiology.

[44]  K. Aonuma,et al.  The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation , 2013 .

[45]  R. Perera,et al.  Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review , 2008, Circulation. Cardiovascular quality and outcomes.

[46]  Albert Hofman,et al.  Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. , 2013, European heart journal.

[47]  Gregory Y H Lip,et al.  The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia , 2012, Chest.

[48]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[49]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[50]  Habib Gamra,et al.  Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry , 2011, Heart.

[51]  G. Lip,et al.  Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation , 2013, Thrombosis and Haemostasis.

[52]  L. Rasmussen,et al.  Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin: A Systematic Review and Meta-analysis , 2013, Stroke.

[53]  J. Cho,et al.  Insights into management of atrial fibrillation in Asia Pacific gained from baseline data from REgistry on cardiac rhythm disORDers (RecordAF-Asia Pacific [AP]) registry. , 2012, The American journal of cardiology.

[54]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[55]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[56]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.